

Fiscal Note 2027 Biennium

Bill#/Title: SB0422.01: Generally revise laws relating to insurance coverage relating to cancer							
Primary Sponsor:	Ellie Boldman		Status:	As Introduced			
☐ Included in the Executive Budget		☐ Needs to be included in HB 2		☐ Significant Local Gov Impact			
☐ Significant Long-Term Impacts		☐ Technical Concerns		☐ Dedicated Revenue Form Attached			
		FISCAL SU	JMMARY				
		FY 2026 <u>Difference</u>	FY 2027 <u>Difference</u>	FY 2028 Difference	FY 2029 <u>Difference</u>		
Expenditures				00	# 0		
Other Proprietary Fur	nd	\$0 \$980,267	\$0 \$1,009,675		\$0 \$1,071,164		
Revenues Other		\$0	\$0	\$0	\$0		
Net Impact		\$0	\$0	\$0	\$0		

Description of fiscal impact

General Fund Balance

SB 422 requires health insurance coverage related to advanced metastatic cancer and prohibits insurers from requiring prior drug failure or proof of a history of failure of a different drug. Additionally, the bill mandates coverage for associated conditions and the side effects of cancer treatment. There is a fiscal impact to the State Health Benefit Plan and the Montana University System Group Insurance Plan from this proposed legislation.

FISCAL ANALYSIS

Assumptions

Commissioner of Higher Education

- 1. This bill, as proposed, will have a fiscal impact on the Montana University System's Group Insurance Plan based on the following assumptions:
 - a. Annual average of plan cost of cancer therapy drugs is \$4,096,650.
 - b. Adjustment for claims incurred but not reported (IBNR) is 1.002.
 - c. Estimated claims trend from midpoint to FY 2026 is 1.170.
 - d. Estimated FY 2026 plan cost of cancer therapy drugs (a x b x c) is \$4,802,667.
 - e. Expected unit cost increase due to bill language is 10%.
 - f. Estimated additional plan cost of cancer therapy drugs under bill (d x e) is \$480,267.
 - g. An inflation factor of 3% was applied for FY 2027, FY 2028, and FY 2029.

Department of Administration

2. From Navitus' perspective, as the pharmacy benefit manager for the State Health Benefit Plan, the company generally does not have a strong preference for specific oncology medications over others. However, an

exception for advanced prostate cancer does exist if the usage of Abiraterone (generic agent) is bypassed for the branded agents like Nubeqa, Erleada, and Xtandi, where the monthly costs are extreme.

- 3. Abiraterone (generic agent) monthly costs range from \$200 to \$250.
- 4. Nubeqa/Erleada/Xtandi (branded agents) monthly costs range from \$11,000 to \$14,000.
- 5. Based on recent State Health Benefit Plan utilization trends, if all applicable claims had been for a branded agent, the additional cost would be approximately \$500,000.
- 6. An inflation factor of 3% was applied for FY 2027, FY 2028, and FY 2029.

Department of Public Health and Human Services

7. The Department of Public Health and Human Services has determined there is no fiscal impact from SB 422, as the proposed legislation does not include Medicaid or the Children's Health Insurance Program (CHIP).

State Auditor's Office

8. The requirements of SB 422 could cause an increase in enforcement on the part of the State Auditor's Office. However, the office will absorb the additional enforcement activities with existing staff.

Fiscal Analysis Table

Commissioner of Higher Educat	ion			
	FY 2026 <u>Difference</u>	FY 2027 <u>Difference</u>	FY 2028 <u>Difference</u>	FY 2029 <u>Difference</u>
Fiscal Impact				
Expenditures				
Benefits	\$480,267	\$494,675	\$509,515	\$524,800
TOTAL Expenditures	\$480,267	\$494,675	\$509,515	\$524,800
Funding of Expenditures				
Other	\$0	\$0	\$0	\$0
Proprietary Fund	\$480,267	\$494,675	\$509,515	\$524,800
TOTAL Funding of Expenditures	\$480,267	\$494,675	\$509,515	\$524,800
Revenues Net Impact to Fund Balance (Re	venue minus Funding	of Expenditures)		
Other	\$0	\$0	\$0	\$0
Proprietary Fund	(\$480,267)	(\$494,675)	(\$509,515)	(\$524,800)
Department of Administration				
	FY 2026 <u>Difference</u>	FY 2027 <u>Difference</u>	FY 2028 Difference	FY 2029 <u>Difference</u>
Fiscal Impact				
Expenditures				
Benefits	\$500,000	\$515,000	\$530,450	\$546,364
TOTAL Expenditures	\$500,000	\$515,000	\$530,450	\$546,364
Funding of Expenditures				
Other	\$0	\$0	\$0	\$0
Proprietary Fund	\$500,000	\$515,000	\$530,450	\$546,364
TOTAL Funding of Expenditures	\$500,000	\$515,000	\$530,450	\$546,364

Revenues

Net Impact to Fund Balance (Revenue minus Funding of Expenditures)

Other Proprietary Fund	\$0 (\$500,000)	\$0 (\$515,000)	\$0 (\$530,450)	\$0 (\$546,364)
STATEWIDE SUMMARY				
	FY 2026 <u>Difference</u>	FY 2027 <u>Difference</u>	FY 2028 Difference	FY 2029 <u>Difference</u>
Fiscal Impact				
TOTAL Fiscal Impact	0.00	0.00	0.00	0.00
Expenditures				
Benefits	\$980,267	\$1,009,675	\$1,039,965	\$1,071,164
TOTAL Expenditures	\$980,267	\$1,009,675	\$1,039,965	\$1,071,164
Funding of Expenditures				
Other	\$0	\$0	\$0	\$0
Proprietary Fund	\$980,267	\$1,009,675	\$1,039,965	\$1,071,164
TOTAL Funding of Expenditures	\$980,267	\$1,009,675	\$1,039,965	\$1,071,164
Revenues				
TOTAL Revenues	\$0	\$0	\$0	\$0
Net Impact to Fund Balance (Reve	nue minus Funding	of Expenditures)	,	
Other	\$0	\$0	\$0	\$0
Proprietary Fund	(\$980,267)	(\$1,009,675)	(\$1,039,965)	(\$1,071,164)

Effect on County or Other Local Revenues or Expenditures Montana Association of Counties

NO SPONSOR SIGNATURE

Sponsor's Initials

Date

3/3/2025

Budget Director's Initials

Date

^{1.} The Montana Association of Counties assumes this coverage will not dramatically increase county health insurance premiums.